Post-Authorization Safety Reporting Program of Canagliflozin-based Therapy in Patients With Type 2 Diabetes in Saudi Arabia
عنوان الدراسة
Post-Authorization Safety Reporting Program of Canagliflozin-based Therapy in Patients With Type 2 Diabetes in Saudi Arabia
داعم الدراسة
Janssen-Cilag International NV
دواء الدراسة
canagliflozin
رقم بروتوكول الدراسة
28431754DI
حالة الدراسة
Ongoing
موقع الدراسة
Specialized Medical Center (Riyadh), Dr. Soliman Fakeeh Hospital (Jeddah), International Medical Center (Jeddah), Dallah Hospital (Riyadh), Almana Hospital (Jubail), Almouasa Hospital (Qatif), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), Dr. Sulaiman Al-Habib Medical Group Rayan (Riyadh), Saudi German Hospital (Jeddah)
مرحلة الدراسة
4
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。